<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38855286</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-1081</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>World journal of otorhinolaryngology - head and neck surgery</Title><ISOAbbreviation>World J Otorhinolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Long-term olfactory loss post-COVID-19: Pathobiology and potential therapeutic strategies.</ArticleTitle><Pagination><StartPage>148</StartPage><EndPage>155</EndPage><MedlinePgn>148-155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/wjo2.165</ELocationID><Abstract><AbstractText>An acute loss of smell emerged as a striking symptom present in roughly half of the people infected with the severe acute respiratory syndrome coronavirus 2&#xa0;(SARS-CoV-2) virus in the early phases of the COVID-19 pandemic. In most COVID-19 patients, olfaction recovers over the course of a few weeks. However, a lasting partial or complete loss of smell, often associated with distorted olfactory perceptions termed parosmia, has emerged as a widespread problem impacting at least 5%-10% of those who experience anosmia due to COVID-19. Our inability to offer effective therapies to this hyposmic or anosmic population, comprising millions of patients, highlights an enormous unmet need for the medical system. Here, we summarize the current understanding of the pathobiology causing acute olfactory loss due to SARS-CoV-2 infection, focusing on how the virus interacts with the peripheral olfactory system, a major site of viral infection. We also explore the problem of long-COVID olfactory dysfunction, which may accompany other persistent systemic disorders collectively termed postacute sequelae of COVID-19. Specifically, we discuss an emerging model focused on unresolved immune cell activity driving ongoing dysfunction. Finally, we review current and future therapeutic approaches aimed at restoring olfactory function.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. World Journal of Otorhinolaryngology &#x2010; Head and Neck Surgery published by John Wiley &amp; Sons Ltd on behalf of Chinese Medical Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-1077-7298</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery &amp; Communication Sciences Duke University Durham North Carolina USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finlay</LastName><ForeName>John B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-3038-1276</Identifier><AffiliationInfo><Affiliation>Medical Scientist Training Program Duke University Durham North Carolina USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5006-6345</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology Duke University Durham North Carolina USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-9612-1696</Identifier><AffiliationInfo><Affiliation>Department of Head and Neck Surgery &amp; Communication Sciences Duke University Durham North Carolina USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology Duke University Durham North Carolina USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Otorhinolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>101690857</NlmUniqueID><ISSNLinking>2095-8811</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hyposmia</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">parosmia</Keyword></KeywordList><CoiStatement>The authors declare no conflict&#xa0;of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>10</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38855286</ArticleId><ArticleId IdType="pmc">PMC11156683</ArticleId><ArticleId IdType="doi">10.1002/wjo2.165</ArticleId><ArticleId IdType="pii">WJO2165</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pence TS, Reiter ER, DiNardo LJ, Costanzo RM. Risk factors for hazardous events in olfactory&#x2010;impaired patients. JAMA Otolaryngol Head Neck Sur. 2014;140:951&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">25170573</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo&#x2010;Rizzo P, Hummel T, Spinato G, et al. Olfactory and gustatory function 3 years after mild COVID&#x2010;19&#x2014;a&#xa0;cohort psychophysical study. JAMA Otolaryngol Head Neck Sur. 2024;150:79&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10636652</ArticleId><ArticleId IdType="pubmed">37943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti Graziadei GA, Graziadei PPC. Neurogenesis and neuron regeneration in the olfactory system of mammals. II. Degeneration and reconstitution of the olfactory sensory neurons after axotomy. J Neurocytol. 1979;8:197&#x2010;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">469573</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung CT, Coulombe PA, Reed RR. Contribution of olfactory neural stem cells to tissue maintenance and regeneration. Nature Neurosci. 2007;10:720&#x2010;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellert TK, Getchell ML, Sparks L, Getchell TV. Characterization of the immune barrier in human olfactory mucosa. Otolaryngol Head Neck Surg. 1992;106:181&#x2010;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Reed RR, Lane AP. Chronic inflammation directs an olfactory stem cell functional switch from neuroregeneration to immune defense. Cell Stem Cell. 2019;25:501&#x2010;513.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778045</ArticleId><ArticleId IdType="pubmed">31523027</ArticleId></ArticleIdList></Reference><Reference><Citation>Borsetto D, Hopkins C, Philips V, et al. Self&#x2010;reported alteration of sense of smell or taste in patients with COVID&#x2010;19: a systematic review and meta&#x2010;analysis on 3563 patients. Rhinology. 2020;58:430&#x2010;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">32626853</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moore MJ, Vasilieva N, et al. Angiotensin&#x2010;converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450&#x2010;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Schroeder S, et al. SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2010;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, Tsukahara T, Weinreb C, et al. Non&#x2010;neuronal expression of SARS&#x2010;CoV&#x2010;2 entry genes in the olfactory system suggests mechanisms underlying COVID&#x2010;19&#x2010;associated anosmia. Sci Adv. 2020;6:eabc5801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID&#x2010;19 patients how SARS&#x2010;CoV&#x2010;2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184:5932&#x2010;5949.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564600</ArticleId><ArticleId IdType="pubmed">34798069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zazhytska M, Kodra A, Hoagland DA, et al. Non&#x2010;cell&#x2010;autonomous disruption of nuclear architecture as a potential cause of COVID&#x2010;19&#x2010;induced anosmia. Cell. 2022;185:1052&#x2010;1064.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808699</ArticleId><ArticleId IdType="pubmed">35180380</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS&#x2010;CoV&#x2010;2 omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2010;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihta KD, Pouwels KB, Peto TE, et al. Omicron&#x2010;associated changes in SARS&#x2010;CoV&#x2010;2 symptoms in the United Kingdom. Clin Infect Dis. 2022;76:e133&#x2010;e141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384604</ArticleId><ArticleId IdType="pubmed">35917440</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell. 2022;185:881&#x2010;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, et al. COVID&#x2010;19&#x2010;related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021;13:eabf8396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Perraud V, Alvarez F, et al. Neuroinvasion and anosmia are independent phenomena upon infection with SARS&#x2010;CoV&#x2010;2 and its variants. Nat Commun. 2023;14:4485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10372078</ArticleId><ArticleId IdType="pubmed">37495586</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M, Clijsters M, Choi S, et al. Anatomical barriers against SARS&#x2010;CoV&#x2010;2 neuroinvasion at vulnerable interfaces visualized in deceased COVID&#x2010;19 patients. Neuron. 2022;110:3919&#x2010;3935.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647025</ArticleId><ArticleId IdType="pubmed">36446381</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo&#x2010;Rizzo P, Menegaldo A, Fabbris C, et al. Six&#x2010;month psychophysical evaluation of olfactory dysfunction in patients with COVID&#x2010;19. Chem Senses. 2021;46:bjab006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929204</ArticleId><ArticleId IdType="pubmed">33575808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadye L, Das D, Sanchez MA, et al. Injury activates transient olfactory stem cell states with diverse lineage capacities. Cell Stem Cell. 2017;21:775&#x2010;790.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728414</ArticleId><ArticleId IdType="pubmed">29174333</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay JB, Brann DH, Abi Hachem R, et al. Persistent post&#x2010;COVID&#x2010;19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium. Sci Transl Med. 2022;14:eadd0484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10317309</ArticleId><ArticleId IdType="pubmed">36542694</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD, et al. SARS&#x2010;CoV&#x2010;2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med. 2022;14:eabq3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral&#x2010;Marques O, Marques A, Giil LM, et al. GPCR&#x2010;specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun. 2018;9:5224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6283882</ArticleId><ArticleId IdType="pubmed">30523250</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarzadeh R, M&#xfc;ller A, Humrich JY, Riemekasten G. When natural antibodies become pathogenic: autoantibodies targeted against G protein&#x2010;coupled receptors in the pathogenesis of systemic sclerosis. Front Immunol. 2023;14:1213804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10285309</ArticleId><ArticleId IdType="pubmed">37359516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral&#x2010;Marques O, Halpert G, Schimke LF, et al. Autoantibodies targeting GPCRs and RAS&#x2010;related molecules associate with COVID&#x2010;19 severity. Nat Commun. 2022;13:1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkin RI, Schmidt L, Velicu I. Interleukin 6 in hyposmia. JAMA Otolaryngol Head Neck Sur. 2013;139:728&#x2010;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">23868430</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira LA, De Vito A, Deiana G, et al. Correlations between IL&#x2010;6 serum level and olfactory dysfunction severity in COVID&#x2010;19 patients: a preliminary study. Eur Arch Otrhinolaryngol. 2022;279:811&#x2010;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117453</ArticleId><ArticleId IdType="pubmed">33983525</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzolla AP, Lovero R, Lo Muzio L, et al. Taste and smell disorders in COVID&#x2010;19 patients: role of interleukin&#x2010;6. ACS Chem Neurosci. 2020;11:2774&#x2010;2781.</Citation><ArticleIdList><ArticleId IdType="pubmed">32786309</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Mao X, Kuang M, et al. Interleukin&#x2010;6 affects the severity of olfactory disorder: a cross&#x2010;sectional survey of 148 patients who recovered from Omicron infection using the Sniffin' Sticks test in Tianjin, China. Int J Infect Dis. 2022;123:17&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">35931372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins C, Surda P, Vaira LA, et al. Six month follow&#x2010;up of self&#x2010;reported loss of smell during the COVID&#x2010;19 pandemic. Rhinology. 2021;59:26&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33320115</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DT, Sabha M, Damm M, et al. Parosmia is associated with relevant olfactory recovery after olfactory training. Laryngoscope. 2021;131:618&#x2010;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">33210732</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen MD. Rhinotopy is disrupted during the re&#x2010;innervation of the olfactory bulb that follows transection of the olfactory nerve. Chem Senses. 2001;26:359&#x2010;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZY, Vaira LA, Boscolo&#x2010;Rizzo P, Walker A, Hopkins C. Post&#x2010;viral olfactory loss and parosmia. BMJ Medicine. 2023;2:e000382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10568123</ArticleId><ArticleId IdType="pubmed">37841969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangadharan V, Zheng H, Taberner FJ, et al. Neuropathic pain caused by miswiring and abnormal end organ targeting. Nature. 2022;606:137&#x2010;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159955</ArticleId><ArticleId IdType="pubmed">35614217</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nature Immunol. 2022;23:210&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. Long&#x2010;term SARS&#x2010;CoV&#x2010;2&#x2010;specific immune and inflammatory responses in individuals recovering from COVID&#x2010;19 with and without post&#x2010;acute symptoms. Cell Rep. 2021;36:109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID&#x2010;19. medRxiv. 2021;595:283&#x2010;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires &#xcd;AT, Steffens ST, Mocelin AG, et al. Intensive olfactory training in Post&#x2010;COVID&#x2010;19 patients: a multicenter randomized clinical trial. Am J Rhinol Allergy. 2022;36:780&#x2010;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309586</ArticleId><ArticleId IdType="pubmed">35866202</ArticleId></ArticleIdList></Reference><Reference><Citation>Altundag A, Yilmaz E, Kesimli MC. Modified olfactory training is an effective treatment method for COVID&#x2010;19 induced parosmia. Laryngoscope. 2022;132:1433&#x2010;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088368</ArticleId><ArticleId IdType="pubmed">35257391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan CH, Jang SS, Lin HFC, et al. Use of platelet&#x2010;rich plasma for COVID&#x2010;19&#x2010;related olfactory loss: a randomized controlled trial. Int Forum Allergy Rhinol. 2023;13:989&#x2010;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877663</ArticleId><ArticleId IdType="pubmed">36507615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien JR, Le Bon SD, Saussez S. Platelet&#x2010;rich plasma injection in the olfactory clefts of COVID&#x2010;19 patients with long&#x2010;term olfactory dysfunction. Eur Arch Otrhinolaryngol. 2023;280:2351&#x2010;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9751511</ArticleId><ArticleId IdType="pubmed">36520209</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens Y, Le Bon SD, Lechien J, et al. Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID&#x2010;19. Eur Arch Otrhinolaryngol. 2022;279:5951&#x2010;5953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9336533</ArticleId><ArticleId IdType="pubmed">35904632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalava A, Benyahia SA, Tico Calzada R, Staat CM. Efficacy of stellate ganglion block in treating long&#x2010;term COVID&#x2010;19&#x2010;related olfactory and gustatory dysfunction: a case series. Cureus. 2023;15:e40929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368190</ArticleId><ArticleId IdType="pubmed">37496529</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson AM, Miller BJ, Kallogjeri D, et al. Stellate ganglion block for the treatment of COVID&#x2010;19&#x2010;induced olfactory dysfunction: a prospective pilot study. Otolaryngol Head Neck Surg. 2024;170:272&#x2010;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10842956</ArticleId><ArticleId IdType="pubmed">37750244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Lee JJ, Perrin A, et al. Efficacy and safety of saline nasal irrigation plus theophylline for treatment of COVID&#x2010;19&#x2010;related olfactory dysfunction: the SCENT2 phase 2 randomized clinical trial. JAMA Otolaryngol Head Neck Sur. 2022;148:830&#x2010;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9264240</ArticleId><ArticleId IdType="pubmed">35797024</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepens EJA, Blijleven EE, Boek WM, et al. Prednisolone does not improve olfactory function after COVID&#x2010;19: a randomized, double&#x2010;blind, placebo&#x2010;controlled trial. BMC Med. 2022;20:445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667850</ArticleId><ArticleId IdType="pubmed">36384737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintschich CA, Dietz M, Haehner A, Hummel T. Topical administration of mometasone is not helpful in post&#x2010;COVID&#x2010;19 olfactory dysfunction. Life. 2022;12:1483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9605508</ArticleId><ArticleId IdType="pubmed">36294918</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan G, Upadhyay A, Khanduja S, Emerick T. Stellate ganglion block for anosmia and dysgeusia due to long COVID. Cureus. 2022;14:e27779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9450932</ArticleId><ArticleId IdType="pubmed">36106285</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel ZM, Holbrook EH, Turner JH, et al. International consensus statement on allergy and rhinology: olfaction. Int Forum Allergy Rhinol. 2022;12:327&#x2010;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">35373533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner M, Liu J, Counsell N, et al. The COVANOS trial&#x2014;insight into post&#x2010;COVID olfactory dysfunction and the role of smell training. Rhinology. 2022;60:188&#x2010;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">35901492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Rissom K, Reden J, H&#xe4;hner A, Weidenbecher M, H&#xfc;ttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;119:496&#x2010;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">19235739</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JH. Olfactory training: what is the evidence. Int Forum Allergy Rhinol. 2020;10:1199&#x2010;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668391</ArticleId><ArticleId IdType="pubmed">32776673</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S, Holbrook LT, Kudlaty K, et al. Numerical evaluation of spray position for improved nasal drug delivery. Sci Rep. 2020;10:10568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324389</ArticleId><ArticleId IdType="pubmed">32601278</ArticleId></ArticleIdList></Reference><Reference><Citation>Inthavong K, Ma J, Shang Y, et al. Geometry and airflow dynamics analysis in the nasal cavity during inhalation. Clin Biomech (Bristol, Avon). 2019;66:97&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">29074148</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P, Camaioni A, Marra P, et al. Effect of ultra&#x2010;micronized palmitoylethanolamide and luteolin on olfaction and memory in patients with long COVID: results of a longitudinal study. Cells. 2022;11:2552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>